Evidence map›Paper›PMID 35711912›Full record

ArticleFrontiers in genetics2022

StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit.

Chiyun Lee, Junxia Lin, Andrzej Prokop, Vancheswaran Gopalakrishnan, Richard N Hanna, Eliseo Papa, Adrian Freeman, Saleha Patel, Wen Yu, Monika Huhn and 8 more

Abstract read
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Chiyun LeeData Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Junxia LinGeorgetown University, Washington, DC, United States.
Andrzej ProkopBiometrics, Oncology R&D, AstraZeneca, Warsaw, Poland.
Vancheswaran GopalakrishnanDiscovery Microbiome, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Richard N HannaEarly Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Eliseo PapaResearch Data and Analytics, R&D IT, AstraZeneca, Cambridge, United Kingdom.
Adrian FreemanDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Saleha PatelDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Wen YuData Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Monika HuhnBiometrics and Information Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
Abdul-Saboor SheikhData Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Keith TanNeuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Bret R SellmanDiscovery Microbiome, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Taylor CohenDiscovery Microbiome, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Jonathan MangionData Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Faisal M KhanData Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Yuriy GusevGeorgetown University, Washington, DC, United States.
Khader ShameerData Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
NCATS NIH HHS UL1 TR001409
6 · The paper itself

Abstract

Target prioritization is essential for drug discovery and repositioning. Applying computational methods to analyze and process multi-omics data to find new drug targets is a practical approach for achieving this. Despite an increasing number of methods for generating datasets such as genomics, phenomics, and proteomics, attempts to integrate and mine such datasets remain limited in scope. Developing hybrid intelligence solutions that combine human intelligence in the scientific domain and disease biology with the ability to mine multiple databases simultaneously may help augment drug target discovery and identify novel drug-indication associations. We believe that integrating different data sources using a singular numerical scoring system in a hybrid intelligent framework could help to bridge these different omics layers and facilitate rapid drug target prioritization for studies in drug discovery, development or repositioning. Herein, we describe our prototype of the StarGazer pipeline which combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits, and is available via https://github.com/AstraZeneca/StarGazer.

Indexed as

data integrationdrug discoveryhybrid intelligencemulti-omicsrepositioningstargazerstreamlittarget prioritization

Identifiers

PMID35711912
PMCPMC9197487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.